###### Strengths and limitations of this study

-   The CRRICH trial is the largest multicentre clinical trial to examine the safety and efficacy of two Chinese compound formulas in patients with acute intracerebral haemorrhage (AICH).

-   This study highlights the possibility that the early use of removing blood stasis herbal medicine in AICH could increase the risk of bleeding, which spurs further research on the safety of Chinese medicines.

-   There were no available data to elucidate the mechanisms of treatment-emergent adverse events (TEAEs) or serious TEAEs.

Introduction {#s1}
============

Acute intracerebral haemorrhage (AICH) accounts for approximately 15%[@R1] of all acute strokes; stroke is the third most common cause of death in most Western countries, following coronary heart disease and cancer.[@R2] AICH has been the leading cause of death in China in recent years[@R4] and is responsible for approximately one-third of the total number of deaths from stroke worldwide.[@R5]

Available specific medical and surgical treatments do not improve prognosis substantially,[@R6] and AICH still accounts for a higher proportion of stroke in Chinese people than in white populations.[@R8] Therefore, traditional Chinese medicine (TCM) physicians in China widely use removing blood stasis (RBS) herbs for the treatment of AICH. Meta-analysis showed that RBS herbal therapy for AICH could improve the neurological function deficit, reduce the volume of haematoma and perihaematomal oedema and lower the mortality rate and dependency.[@R9] It is possible that RBS herbal medicine promotes haematoma absorption and improves the recovery of neurological impairment[@R10]; RBS herbal medicine has already been included by guidelines for the management of spontaneous ICH. However, sufficient evidence of long-term benefits and risks of superacute stage is lacking. RBS herbals, such as *Hirudo nipponica Whitman*, which acts as a thrombin inhibitor with anticoagulant pharmacological effects, may cause rebleeding risk in clinical practice.[@R12] A total of 90% of haematoma growth, which plays an important role in prognosis, occurs within a 6-hour time window.[@R13] Therefore, a confirmation of the safety and efficacy of RBS herbal medicines in the treatment of early-stage AICH is urgently needed.

We performed a retrospective study that demonstrated that RBS herbal medicine for patients with AICH was safe and effective.[@R14] However, little additional evidence of the safety and efficacy of this treatment exists. We designed a multicentre, three-group, prospective, randomised, double-blinded and placebo-controlled clinical trial on haematoma enlargement in patients with AICH treated with RBS herbal medicine within a 6-hour time window from symptom onset (CRRICH: Clinical re‑evaluation of removing blood stasis therapy in treating acute intracerebral hemorrhage) to evaluate its safety and efficacy in patients with AICH and to provide a high level of evidence for clinical practice.

Methods {#s2}
=======

Study design {#s2a}
------------

The CRRICH trial was a multicentre, randomised, double-blinded, placebo-controlled, parallel-group study to assess the safety and efficacy of RBS herbal medicine in patients with AICH. This trial is registered at clinicaltrials.gov (NCT01918722), and the research design proposal has been published.[@R15]

Participants {#s2b}
------------

Patients with a Glasgow Coma Scale (GCS) score ≥6 were enrolled if they were ≥18 years of age and had a clinical diagnosis of ICH confirmed with CT within 6 hours of onset. All participants signed an informed consent form. If the participants did not have the capacity to sign the informed consent for serious condition or illiteracy, the researcher will explain the informed consent to the patients or their authorised immediate family. Weighing the pros and cons of both sides, their immediate family will decide whether to sign the informed consent on behalf of the patient. Patients who suffered secondary ICH resulting from trauma, brain tumour, blood diseases, arteriovenous malformation or aneurysm were excluded. A detailed patient history was recorded. Online [supplementary table S1](#SP1){ref-type="supplementary-material"} provides a full list of study inclusion and exclusion criteria during the screening period.
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Randomisation and blinding {#s2c}
--------------------------

Patients were randomised to receive placebo, ICH-1 or ICH-2 in a 1:1:1 ratio with a stratification and block size of 6 using the PROC PLAN process in SAS software V.9.13. Stratified block and randomisation were concealed using sequentially numbered opaque envelopes. Persons involved in the study, including the investigators, patients and data analysts, were blinded to treatment assignment during double-blinded treatment until the end of follow-up. Only the data administrators were permitted access to unblinded data.

Procedures {#s2d}
----------

Enrolment, intervention and follow-up {#s2e}
-------------------------------------

Patients were recruited from October 2013 through May 2016 at 14 hospitals in China (see online [supplementary table S2](#SP1){ref-type="supplementary-material"}). The study consisted of a screening and randomisation period (≤6 hours poststroke), a 10-day double-blinded treatment period and a 3-month follow-up period (see online [supplementary figure S1](#SP1){ref-type="supplementary-material"}). Participants were randomly assigned to one of three treatment groups at a ratio of 1:1:1 during the double-blinded treatment (shown in the online [supplementary table S3 and S4](#SP1){ref-type="supplementary-material"}): (1) The ICH-1 group received the ICH-1 formula, which consisted of eight herbs including RBS medicines; (2) The ICH-2 group received the ICH-2 formula, which consisted of six herbal medicines without RBS herbs (*H. nipponica Whitman* and *Tabanus bivittatus Matsumura*) in the same doses as those in the ICH-1 group, with the remaining dose filled with a placebo; and (3) The placebo group received a placebo that included dextrin and farina. Each unit of TCM or placebo was dissolved in 200 mL of boiling water. Each patient received 200 mL orally or through a nasogastric tube twice daily for 10 days (see online [supplementary table S3](#SP1){ref-type="supplementary-material"}).

Patients were followed up for 3 months after the 10-day double-blinded treatment period. Patients were hospitalised in stroke units and received standard stroke care in accordance with local guidelines, which included general supportive care, treatment of acute complications and rehabilitation. Astringents and other RBS drugs were prohibited. Visits were scheduled at baseline, 24 hours poststroke and at the end of the treatment period, with a single visit scheduled 3 months poststroke (see online [supplementary figure S1](#SP1){ref-type="supplementary-material"}). Adverse events (AEs), treatment compliance and concomitant medication use were reported during each visit. Participants were randomly assigned to one of three treatment groups at a ratio of 1:1:1 during double-blinded treatment.

Primary and secondary outcomes {#s2f}
------------------------------

The incidence of haematoma enlargement, which was defined as the percentage of participants who experienced haematoma enlargement, was the primary outcome of the study. Haematoma enlargement was operationally defined as an increase in haematoma volume of \>33% or 12.5 mL, as measured on image analysis on the 24-hour CT compared with the baseline CT scan. Haematoma volume was measured using the ABC/2 Coniglobus formula[@R16] at 24 hours after onset. The same measurement was performed on days 10--14 as a primary outcome measure. National Institutes of Health Stroke Scale (NIHSS) scores range from 0 (normal) to 42 (coma with quadriplegia); and modified Rankin Scale (mRS) scores range from 0 (no symptoms or disability) to 6 (death). Both of them can be used to evaluate the clinical outcomes. The following secondary end points were assessed: change in NIHSS score at 3 months, mortality at 3 months and poor prognosis rate, which was defined as the proportion of patients who died or were severely disabled based on an mRS score ≥5 at 3 months.[@R17] Safety data focused on treatment-emergent AEs (TEAEs). TEAEs were defined as AEs that first occurred or worsened (increased in severity) after the first dose of study drug. The patient spontaneously reported TEAEs in response to an open-ended question from the contact person at each visit. A worsened patient condition, prolonged patient hospitalisation and life-threatening TEAEs in patients were reported as serious AEs (TEsAEs). Abnormal laboratory values that constituted a sAE or led to the discontinuation of experimental drugs were also reported as TEsAEs. Online [supplementary table S5](#SP1){ref-type="supplementary-material"} provides a full list of all primary, secondary and safety end points.

Statistical analyses {#s2g}
--------------------

All reported efficacy analyses were predefined and based on the full analysis set (FAS) (patients who were randomised and received any study medication) according to the intent-to-treat (ITT) principle. Supportive analyses were performed in a predefined per-protocol population set (PPS), which included FAS patients who did not have one or more key protocol deviations, including violations of inclusion and exclusion criteria. The last observation for surviving patients with missing outcome data was carried forward. Patients who had died by the 90-day follow-up were assigned a Barthel index score of 0 and an mRS score of 6, and the last recorded NIHSS score was carried forward. The incidence of haematoma enlargement at 24 hours (primary end point), the rate of poor prognosis and the incidence of total TEAEs among the three groups were analysed using the χ[@R2] test. The incidence of haematoma enlargement on days 10--14 (primary end point) and mortality among the three groups were compared using Fisher's exact test. The mean differences in NIHSS score among groups were analysed using one-way analysis of variance. Demographic characteristics and serious TEAEs were summarised using descriptive statistics.

Power and sample size were determined using relative haematoma volume at 24 hours as the primary outcome variable. A total of 285 participants were required at the final follow-up to provide 90% power with a two-sided alpha level at 0.05 to test the primary efficacy, which was calculated using the PASS (Power Analysis and Sample Size) software programme (licensed by NCSS, LLC). A total of 360 participants were needed for primary outcome randomisation assuming a dropout rate of 20%, with 120 patients per treatment arm. The statistical package STATA (V.13.1) was used for all statistical analyses.

Patient and public involvement statement {#s2h}
----------------------------------------

While we put forward the research question and outcome measures, the patients' priorities, experience and preferences were fully considered by a survey. Patients were involved in the recruitment to and conduct of the study. The results would be disseminated to study participants by posting a letter. The CRRICH trial was a randomised controlled trial, and the patients themselves had fully assessed the burden of the intervention. Patient advisors should also be thanked in the contributorship statement/acknowledgements.

Funding and ethical statements {#s2i}
------------------------------

The State Administration of Traditional Chinese Medicine of the PRC (SATCM) awarded Guangdong Provincial Hospital of TCM (GPHTCM) SATCM grant no: ZDJX2012074 and provided input during the study period. This report was an independent study supported by SATCM and performed by the GPHTCM in a SATCM--GPHTCM partnership. The viewpoints stated in this manuscript are those of the authors and may not represent the opinions of SATCM, GPHTCM or the Public Health Bureau. The SATCM and GPHTCM approved the decision to submit this paper for publication. Dr Jianwen Guo had full access to all study data and had final responsibility for the decision to submit for publication.

Each respective institutional review board or ethics committee approved the study protocol, which followed the established Good Clinical Practice guidelines. All patients provided written informed consent to participate in the study. An independent contract research organisation, S&R (Department of Science and Research of Guangdong Provincial Hospital of Chinese medicine), managed the administration, coordination and monitoring of the study, including researcher training, study inspection, data management and statistical analyses, with oversight by the SATCM.

Results {#s3}
=======

Study population {#s3a}
----------------

Patient recruitment began in October 2013, and the study ended in May 2016. A total of 5589 individuals with ICH were screened ([figure 1](#F1){ref-type="fig"}). The most frequent reasons for exclusion in descending order were time window \>6 hours, refusal to participate, secondary ICH (ie, not AICH) and other reasons. A total of 319 of the 324 randomised patients (105 placebo, 108 ICH-1, 111 ICH-2) received the assigned treatment following the elimination of five patients (one patient for missing the time window, one patient for kidney failure, one patient for secondary ICH, one patient for surgery within 24 hours and one patient withdrew consent). Therefore, only the 319 participants who underwent randomisation and received study medication were included in the FAS and safety analysis set based on ITT. Twenty-three patients in the FAS did not completely adhere to the protocol and dropped out during the treatment period. A total of 296 patients were included in the PPS (see [figure 1](#F1){ref-type="fig"} for patient flow diagram). The mean dropout rate was \<8%. [Table 1](#T1){ref-type="table"} presents the demographics and baseline characteristics of the FAS, which were well balanced with no significant between-group differences. The mean age was 62.5±12.7 years (mean ±SD, n=319); 65.5% of the patients were men, and 98.7% were ethnic Han. The median GCS score was 15 (range, 3 to 15), and the mean NIHSS score was 8 (range, 0 to 47). The deep grey matter was involved in 93.4% of cases, and the lobar regions were involved in 6.6% of cases. The baseline characteristics of the three treatment groups were similar. The mean volume of the ICH at baseline for all patients was 11.0 mL (range, 0.3 to 86.7 mL), which was similar in the three groups ([table 1](#T1){ref-type="table"}). The mean time from onset of symptoms to admission was 3.36±1.49 hours, and the mean time from onset of symptoms to treatment was 4.10±1.38 hours. Fourteen per cent of patients were treated within 3 hours after symptom onset. Two patients were treated outside of the 6-hour time window. The timing of the treatment was similar in the three groups ([table 1](#T1){ref-type="table"}).

![Enrolment and follow-up. AEs, adverse events; FAS, full analysis set; PPS, per-protocol population set; RBS, removing blood stasis; ICH denotes intracerebral haemorrhage; ICH-1 denotes herbal medicine with RBS herbals *hirudo* and *tabanus* (eight herbals); ICH-2 denotes herbal medicine without RBS herbals *hirudo* or *tabanus* (six herbals).](bmjopen-2018-024932f01){#F1}

###### 

Baseline characteristics and treatment timing

  --------------------------------------------------------------------------------------------------------
  Variable                                               Placebo (n=104)   ICH-2 (n=108)   ICH-1 (n=107)
  ------------------------------------------------------ ----------------- --------------- ---------------
  Age (year)                                             61.95±13.38       62.56±12.64     62.84±12.23

  Sex n (%)                                                                                

   Male                                                  69 (66.3)         69 (63.9)       71 (66.4)

   Female                                                35 (33.7)         39 (36.1)       36 (33.6)

  Ethnic group n (%)                                                                       

   Ethnic Han                                            103 (99.0)        105 (97.2)      107 (100.0)

   Not ethnic Han                                        1 (1.0)           3 (2.8)         0 (0)

  Hemisphere haematoma n (%)                                                               

   Left hemisphere                                       44 (42.3)         53 (49.1)       56 (52.3)

   Right hemisphere                                      59 (56.7)         54 (50.0)       51 (47.7)

  Supratentorial haematoma n (%)                                                           

   Putamen or globus pallidus                            69 (66.3)         72 (66.7)       64 (59.8)

   Thalamus                                              19 (18.3)         24 (22.2)       28 (26.2)

   Lobar hemisphere                                      10 (9.6)          7 (6.5)         4 (3.7)

   None                                                  6 (5.8)           5 (4.6)         11 (10.3)

  Subtentorial haematoma n (%)                                                             

   Cerebellum                                            4 (3.8)           2 (1.9)         7 (6.5)

   Pons or midbrain                                      2 (2.0)           4 (3.7)         5 (5.0)

   None                                                  98 (94.2)         102 (94.4)      95 (88.8)

  Intraventricular haemorrhage n (%)                                                       

   Yes                                                   17 (16.3)         19 (17.6)       25 (23.4)

   No                                                    87 (83.7)         89 (82.4)       82 (76.6)

   GCS score                                             14.18±1.86        13.77±2.34      13.76±2.06

   NIHSS score                                           7.88±5.24         9.00±7.24       9.13±6.16

   Volume of the intracerebral haemorrhage at baseline   9.82±7.45         11.56±9.67      11.57±11.55

   Systolic BP at time of admission\                     171.34±28.04      174.14±23.72    172.04±22.53
   (mm Hg)                                                                                 

   Time from onset to treatment (hour)                   4.31±1.38         4.02±1.35       3.97±1.39

   Time from onset to admission (hour)                   3.61±1.54         3.08±1.47       3.05±1.63
  --------------------------------------------------------------------------------------------------------

ICH denotes intracerebral haemorrhage; GCS, Glasgow Coma Scale (scores range from 15 \[normal\] to 3 \[deep coma\]); NIHSS, National Institutes of Health Stroke Scale (scores range from 0 (normal) to 42 (coma with quadriplegia)); BP, blood pressure.

Primary outcome (radiographic outcomes) {#s3b}
---------------------------------------

At 24 hours, a total of 319 baseline CT scans and 315 CT scans were available for analysis. The incidence of haematoma enlargement were 7.8% in the placebo group, 12.3% in the ICH-1 group and 7.5% in the ICH-2 group. There was no significant difference in the incidence of haematoma enlargement at 24 hours among the three groups (p=0.409). The incidence of haematoma enlargement on days 10--14 was 1.1% in the placebo group, 3.1% in the ICH-2 group and 1.1% in the ICH-1 group. There was also no significant difference among the three groups in the incidence of haematoma enlargement on days 10--14 (p=0.625) ([table 2](#T2){ref-type="table"}).

###### 

Primary outcome and secondary outcomes

                                                                                      Placebo             ICH-2            ICH-1            Differences among groups
  ----------------------------------------------------------------------------------- ------------------- ---------------- ---------------- --------------------------
  Primary outcome: the incidence of haematoma enlargement at 24 hours and at day 14                                                         
   At 24 hours                                                                        8/104 (7.8)         8/108 (7.5)      13/107 (12.3)    0.409
   On days 10--14                                                                     1/92 (1.1)          3/97 (3.1)       1/91 (1.1)       0.625
  Haemorrhage volumes (mL) at baseline and follow-up                                                                                        
   At baseline                                                                        9.82±7.45           11.56±9.67       11.57±11.55      0.284
   At 24 hours                                                                        9.71±6.94           11.97±10.02      14.44±19.33      0.313
   Percent increase from baseline-means% (95% CI)                                     −14.1 (4.5--32.7)   3.4 (0.2--6.5)   41 (9.4--91.4)   0.22
   Millilitres of increase from baseline                                              −0.13±1.41          0.22±2.24        3.13±16.10       0.168
  Secondary outcomes:                                                                                                                       
   NIHSS\* at 3 months                                                                3.58±5.32           3.58±5.32        3.58±5.32        0.475
   Mortality at 3 months                                                              4/104 (3.8)         1/108 (0.9)      3/107 (2.8)      0.328
   Poor prognosis (mRS≥5)                                                             7/99 (7.1)          5/105 (4.8)      6/100 (6.0)      0.783
   Total TEAEs                                                                        6/104 (5.8)         3/108 (2.8)      13/107 (12.1)    0.022

The values are expressed as n/N(%) within group or the means±SD;

\*Denotes the number of patients at 3 months: 104 in the placebo group, 107 in the ICH-2 group and 105 in the ICH-1 group.

ICH denotes intracerebral haemorrhage; NIHSS, National Institutes of Health Stroke Scale; TEAEs, treatment-emergent adverse events.

Secondary outcomes (clinical outcomes) {#s3c}
--------------------------------------

Mortality at 3 months was approximately 2.6% in the three groups ([table 2](#T2){ref-type="table"}). Poor prognosis (ie, the proportion of patients who died or were severely disabled, mRS ≥5) did not differ significantly among the three groups. There are less more patients with poor prognosis after ICH-2 treatment, but no significant difference compared with placebo treatment ([table 2](#T2){ref-type="table"}). The distributions of outcomes on the mRS ([figure 2](#F2){ref-type="fig"}) were similar among the three groups. The differences in the NIHSS scores at 3 months among the three groups were not significant ([table 2](#T2){ref-type="table"}).

![Clinical outcome at 90 days according to the modified Rankin Scale. The modified Rankin Scale evaluates global disability and handicap. Scores range from 0 (no symptoms or disability) to 6 (death). There were no significant differences among the three groups.](bmjopen-2018-024932f02){#F2}

Adverse events {#s3d}
--------------

There were altogether 35 AEs reported by investigators, of which 22 AEs may have been TEAEs. All the TEAEs occurred during the double-blinded treatment period (within 2 weeks). TEAEs occurred in 13 (12.1%) ICH-1-treated patients, 3 (2.8%) ICH-2-treated patients and 6 (5.8%) placebo-treated patients. The patterns of TEAEs were similar in the three groups, but the overall frequencies of TEAEs among the three groups were significantly different (p=0.022), as shown in [table 2](#T2){ref-type="table"}. And the paired comparisons showed that the test for difference in the overall TEAEs rate between group ICH-1 and group ICH-2 yields a p value of 0.029. [Table 3](#T3){ref-type="table"} shows the TEAEs that occurred during the study. The most frequent event was diarrhoea, and its incidence was similar in the three treatment groups. Treatment was discontinued because of TEsAEs in three (1.9%) ICH-1-treated patients. The three cases with TEsAEs (two cases of gastrointestinal bleeding, one case of cerebral hernia) reported by investigators occurred in ICH-1-treated patients. There was no consistent pattern to this difference, and all serious TEAEs occurred within the 10-day drug treatment period. There were no statistically significant differences in the incidence or type of serious TEAEs leading to death among groups (data not shown). There was no relationship between TEAEs, serious TEAEs or mortality and poor outcome (data not shown).

###### 

Treatment-emergent adverse events

                                Placebo       ICH-2         ICH-1
  ----------------------------- ------------- ------------- -------------
  Vomiting                      1/104 (1.0)   0/108 (0.0)   2/107 (1.9)
  Gastrointestinal bleeding\*   0/104 (0.0)   0/108 (0.0)   2/107 (1.9)
  Stomachache                   0/104 (0.0)   0/108 (0.0)   1/107 (0.9)
  Chest congestion              1/104 (1.0)   0/108 (0.0)   0/107 (0.0)
  Cerebral hernia\*             0/104 (0.0)   0/108 (0.0)   1/107 (0.9)

The values are expressed as n/N (%) within group. All adverse events are listed in order of frequency from the overall study period (90 days); adverse events were collected from investigator reports. The principal investigator at each site determined whether an adverse event or serious adverse event was related to the intervention.

\*Indicates TEAEs.

TEAEs, treatment-emergent adverse events.

Discussion {#s4}
==========

ICH-1 administration within 6 hours after the symptom onset of ICH did not significantly reduce haematoma growth and failed to improve survival or functional outcome at 90 days. Conversely, compared with the ICH-2, the incidence of TEAEs showed an increasing trend in the ICH-1 group (p=0.029, ICH-1 vs ICH-2). Significant increases were also demonstrated in total TEAE frequency and in serious TEAEs in the ICH-1 group. Three serious bleeding events occurred in the ICH-1 group (ICH-1, with two RBS herbals), including two cases of gastrointestinal bleeding and one case of intracerebral rebleeding. All three cases were fatal serious TEAEs ([table 2](#T2){ref-type="table"}). These data suggest that RBS treatment for ICH patients within 6 hours of symptom onset is a safety concern. However, no data were available to suggest a mechanism for this effect. The possible rebreeding mechanism is that RBS medicine, such as *H. nipponica Whitman*, which has anticoagulant pharmacological effects, could increase bleeding risk according to the previous literature.[@R12]

As can be seen from the [table 2](#T2){ref-type="table"}, ICH-2 treatment was least vulnerable to poor prognosis and TEAEs. Therefore, ICH-2 formula would have the potential to be an effective herbal drug for ICH patients of superacute stage.

This result contrasts with the clinical benefit demonstrated in a previous meta-analysis,[@R9] which included nine randomised controlled clinical trials with 798 individuals, demonstrating that RBS therapy for acute ICH reduced brain haematoma and cerebral oedema volumes, improved the neural function and reduced the mortality and disability rates with fewer TEAEs. The present trial revealed significant heterogeneity compared with the studies included in the meta-analysis, possibly because of differences in the intervention time window. This research is the first prospective, multicentre, randomised, double-blind, placebo-controlled study to assess the efficacy and safety of ICH-1 in patients with AICH within a 6-hour time window from symptom onset, unlike prior studies that examined these effects within a 24-hour or later intervention time window. Earlier RBS administration increased the risk of bleeding events (eg, gastrointestinal bleeding or intracerebral rebleeding), which counteracted the benefit to some extent.

The primary outcome of the incidence of haematoma enlargement, which is an independent prognostic determinant of mortality and poor prognosis,[@R18] was also used to assess safety. The incidence of haematoma enlargement at 24 hours in the three groups in the CRRICH trial (placebo, ICH-2, and ICH-1) were 7.8%, 7.5% and 12.3%, respectively, and they were not significantly different ([table 2](#T2){ref-type="table"}). The mean incidence of haematoma enlargement was only 9.2%, which was far lower than the mean level of 18%--30%.[@R18] The main reasons for lower haematoma expansion incidence may include the following: (1) the investigators' inclination toward surgery in patients with AICH with large haemorrhage volumes within 24 hours of onset, which resulted in the exclusion of patients susceptible to rebleed in the study; and (2) patients with terrible and unstable conditions who were prone to haematoma expansion were excluded by investigators privately for fear that deterioration risk would increase during study.

Haematoma growth is an independent determinant of death and disability.[@R19] Therefore, haematoma expansion may be an attractive therapeutic target.[@R20] However, no proven specific therapies or treatments exist to prevent haematoma expansion or improve outcomes after ICH. Sufficient evidence-based medical research to prove that minitraumatic surgeries and the present available medicines provide ideal treatment is lacking.[@R6]

Herbal medicine in China has been used to treat ICH for at least 2000 years, and RBS herbal medicines are listed in the 2010 Chinese Pharmacopoeia.[@R22] Dr Si reported the earliest available literature on AICH with RBS herbal medicine therapy in 1981.[@R23] Another RBS medicine, Naoxuekang capsule, was approved as routine treatment for patients with AICH by the Chinese State Food and Drug Administration[@R22] (Naoxuekang capsule, register no. Z10960009). RBS herbal medicines have been studied in patients with AICH in more than 200 clinical studies over the past 30 years, and they have gradually come to be considered a regular therapy.[@R24] AICH management guideline in China cited this treatment.[@R25] However, safety evidence in the early stage of AICH is lacking. Some studies demonstrated that 30% of ICH patients suffered continued bleeding within 6 hours of onset.[@R26] Some research has provided low-level evidence of the safety of RBS herbal medicine for superacute cerebral haemorrhage, but whether RBS herbal medicine administration in an early-stage induced haematoma growth was not known because RBS herbal medicine exhibits an anticoagulation effect.[@R27] Marketed RBS drugs that are clinically recognised and widely used did not illustrate a specific application time window. Early administration of RBS drugs may cause haematoma expansion and increase the risk of death and serious disability. The CRRICH trial was a prospective, double-blinded, multicentre clinical trial that demonstrated that early administration of RBS drugs did not increase haematoma growth but significantly increased TEAEs.

The CRRICH trial is the largest clinical trial to investigate the safety and efficacy of a Chinese compound formula in patients with AICH. Three other influential RCT trials of medical treatments with drugs, including FAST, INTERACT2 and CHANT, that exhibit mechanisms very different from those of RBS used similar methods to evaluate the safety and efficacy and found no significant benefit.[@R17]

Data from the clinical study suggested that the administration of RBS herbal medicine should be avoided in patients with AICH during the initial 6-hour time window from stroke onset to avoid the increased risk of bleeding. Further clinical studies should be performed to confirm the safety and efficacy of these agents beyond the 6 hours of ICH onset. This research suggests that the early administration of RBS herbal medicine in ICH patients increases the risk of bleeding, such as gastrointestinal bleeding, and haematoma growth. Some Chinese patent drugs (Naoxuekang capsule \[Z10960009\], Naoxuekang pill \[Z20050312\] or Naoxuekang drop pills \[Z10980039\]), which primarily consist of *Hirudo nipponica Whitman*, should be re-evaluated and used under supervision. The relevant manufacturers should revise the drug instructions and add a warning, 'Do not use for superacute cerebral haemorrhage within 6 hour from onset', if necessary.

This study had some limitations. First, there were no available data to elucidate the mechanism of TEAEs or serious TEAEs. Second, there was a significant difference in the number of patients among research centres. Third, the investigators preferred to study patients with minor haematoma volume because they were afraid of the rebleed risk from the herbal medicine.

Summary {#s4a}
-------

This study demonstrates that ultra-early administration, namely within 6 hours of ICH onset, of RBS herbal medicine for patients with AICH increased the risk of bleeding, such as gastrointestinal bleeding, and haematoma growth. This study also shows that RBS herbal medicine did not exert significantly beneficial effects on clinical outcomes in hypertensive ICH patients in the ultra-early stage. These results support the idea that the ultra-early administration of RBS herbal medicine is unsafe and has a low efficacy. Future high-quality research should further assess the efficacy and safety of RBS herbal medicine for intracerebral haemorrhage beyond the 6-hour time window.
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